^{Stem Cell and Regenerative Medicine}

Biography

Biography: Zhengping Liu

Abstract

Ceasarean delivery has already become a very common way of delivery around the world, especially in low-income countries. Hypertrophic scars and wound infections have affected younger mothers and frustrated obstetricians for a long time. Previous studies have demonstrated that MSCs are involved in enhancing diabetic wound healing. Therefore, this study is designed to investigate the safety and efficacy of using MSCs in the treatment for the caesarean section skin scars. This trial is a prospective, randomized, double-blind, placebo-controlled, single-center trial with three parallel groups. Eligible participants are randomly allocated to placebo, low-dose (3×10⁶ cells transdermal hydrogel MSCs) or high-dose group (6×10⁶ cells transdermal hydrogel MSCs), once a day for consecutive six days. Study duration is 6 months. The primary outcome of this trial is to evaluate the change of Vancouver scar scale during the 6 months. Adverse events, including severe and slight signs and symptoms, are documented in case report form. The study is conducted at the Department of Obstetric of Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan. The first participant was recruited on September 14^th, 2016. We hope to complete enrolment for the trial by September 2017 with all 6-month follow-up data expected by March 2018. This trial is the first investigation of the potential for therapeutic use of MSCs for the management of women’s skin scar after cesarean delivery. The results will give us an effective therapeutic strategy to combat caesarean section skin scars, even in the uterine scar.